Terms ending in 2039
Every in-force patent on Schrödinger, Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,759,756 | Antagonists of Human Integrin (ALPHA4)(BETA7) In force · High confidence | Morphic Therapeutic, Inc. | In force | High confidence | |
| US 11,710,543 | Methods for Predicting an Active Set of Compounds Having Alternative Cores, and Drug Discovery Methods Involving the Same In force · High confidence | Schrödinger, Inc. | In force | High confidence | |
| US 11,021,480 | Inhibiting (ALPHA-V)(BETA-6) Integrin In force · High confidence | Morphic Therapeutic, Inc. | In force | High confidence | |
| US 11,414,431 | Substituted Pyrazolo[1,5-a]pyrimidines as TYK2 Inhibitors In force · High confidence | Nimbus Lakshmi, Inc. | In force | High confidence | |
| US 12,221,453 | SUBSTITUTED PYRAZOLO[5',1':2,3]PYRIMIDO[5,4-b][1,4]OXAZINES AS TYK2 INHIBITORS In force · High confidence | Nimbus Lakshmi, Inc. | In force | High confidence | |
| US 11,739,087 | Inhibiting (ALPHA-V)(BETA-6) Integrin In force · High confidence | Morphic Therapeutic, Inc. | In force | High confidence | |
| US 11,651,840 | Accounting for Induced Fit Effects In force · High confidence | Schrödinger, Inc. | In force | High confidence | |
| US 11,492,341 | Acly Inhibitors and Uses Thereof In force · High confidence | Nimbus Discovery, Inc. | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
2 of these are in force and held by Schrödinger, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.